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In this study, we investigated the role of hyaluronan (HA) in non-small cell lung cancer (NSCLC) since close association
between HA level and malignancy has been reported. HA is an abundant extracellular matrix component and its synthesis is
regulated by growth factors and cytokines that include epidermal growth factor (EGF) and interleukin-1β (IL-1β). We showed
that treatment with recombinant EGF and IL-1β, alone or in combination with TGF-β, was able to stimulate HA production in
lung adenocarcinoma cell line A549. TGF-β/IL-1β treatment induced epithelial to mesenchymal-like phenotype transition (EMT),
changing cell morphology and expression of vimentin and E-cadherin. We also overexpressed hyaluronan synthase-3 (HAS3)
in epithelial lung adenocarcinoma cell line H358, resulting in induced HA expression, EMT phenotype, enhanced MMP9 and
MMP2 activities and increased invasion. Furthermore, adding exogenous HA to A549 cells and inducing HA H358 cells resulted
in increased resistance to epidermal growth factor receptor (EGFR) inhibitor, Iressa. Together, these results suggest that elevated
HA production is able to induce EMT and increase resistance to Iressa in NSCLC. Therefore, regulation of HA level in NSCLC may
be a new target for therapeutic intervention.
1.Introduction
Lung cancer is the leading cause of death, both in the
United States as well as worldwide. There are two main
classiﬁcations for lung cancer, namely, non-small cell lung
cancer (NSCLC) that accounts for 75%–80% and small cell
lung cancer that make up the remaining 20%–25%. Despite
extensive research in diagnostic and treatment strategies, the
o v e r a l l5 - y e a rs u r v i v a lr a t ei so n l y8 % – 1 4 %[ 1] .T h e r ei sa n
urgentneedtoidentifypotentialtherapeutictargetsfornovel
therapeuticapproachestomanagethisdisease.Onepotential
target is HA as it has previously been reported that high HA
expression in the tumor cells and stroma of patients with
lung adenocarcinoma, a subtype of NSCLC, is associated
poor tumor diﬀerentiation and high recurrence rate [2].
HA is a linear unsulfated glycosaminoglycan composed
of repeating disaccharides of D-glucuronic acid and N-
acetylglucosamine, whose molecular weight can reach up to
107 dalton [3]. The synthesis of HA is regulated by three
mammalian enzymes namely HAS1, HAS2, and HAS3 [4]
whichareintegralplasmamembraneproteinswiththeactive
sitesthatarelocatedattheintracellularfaceofthemembrane
[5]. Each enzyme synthesizes HA but at diﬀerent rates and
terminatessynthesiswithpolymerchainsofdiﬀeringsize[6].
HAS3 is the most active that drives the synthesis of short
HA chains (100 to 1000kDa) and is thought to contribute to
the pericellular matrix or may interact with cell surface HA
receptors thereby triggering signaling cascades and profound
changes in cell behavior. HAS3 is known to contribute to the
malignant phenotype in many malignancies [7]. HAS1 is the2 Journal of Biomedicine and Biotechnology
least active and drives the synthesis of high molecular weight
HA (2000kDa). HAS2 is more catalytically active than HAS1
and it also produces high molecular weight HA (2000kDa)
andisimplicatedindevelopmentalprocessesinvolvingtissue
expansion and growth. The existence of these three diﬀerent
isoforms implies that HA functions are diversely regulated
through the activities and expression of the HAS genes.
Various growth factors and cytokines including TFG-β1[ 8],
EGF [9] and heregulin [10] have been shown to modulate
HAS expressions and HA production in tumor cells.
Increased synthesis of HA is often associated with
malignancy in many diﬀerent tumors including lung cancer
[2], ovarian cancer [11], and breast cancer [12]. HA
production is contributed by the tumor-associated stroma
and/ortumorcells[13,14].ThisassociationbetweenHAand
tumorigenesis have been supported by both in vitro and in
vivostudieswherebyoverexpressionofvariousHASisoforms
caused increased growth or metastasis in ﬁbrosarcoma [15],
prostate[16],colon[17],andbreast[18]cancers.Conversely,
inhibitionofvariousHASgenesandtherebydownregulation
of HA production caused a decreased in tumor growth in
prostate carcinoma cells [19] and metastasis in breast cancer
[20]. Furthermore, in vitro studies have also demonstrated
that exogenous addition of HA to tumor cells was able
to promote cell migration [21]i no v a r i a nc a n c e rc e l l
line, induces chemoresistance in NSCLC and meloma cell
lines [22, 23], and promotes, cell invasion by stimulating
production of metalloproteinases (MMPs) in lymphoma
and small lung cancer cell lines [24, 25]. These studies
highlight the importance of hyaluronan in the progression
of tumorigenesis.
EMT is a process that plays important role in normal
development and in cancer progression [26]. EMT involves
morphological and biochemical changes resulting in the
loss of E-cadherin, an epithelial marker while gaining mes-
enchymal markers such as vimentin or ﬁbronectin. Besides,
EMT has also been reported to induce the production
of MMPs resulting in the tumor cells gaining invasive
abilities which represents one of the hallmarks of cancer
[27]. Downregulation of E-cadherin is associated with poor
prognosis in NSCLC [28, 29] and prostate cancer [30, 31]
indicating that E-cadherin has a tumor suppressing role.
EGFR is expressed in a variety of human malignancies
and EGFR-TKIs have been used in treatment for a number
of cancers including NSCLC [32]. It has been reported that
EMT is a determinant of sensitivity of NSCLC [33, 34]a s
well as head and neck cancer [35, 36]. In this context, tumor
cellswithmesenchymalphenotypewerelesssensitivetothese
inhibitors. Overexpression of E-cadherin in in vitro study
restored the sensitivity to EGFR-TKIs [37], thus indicating
that E-cadherin expression has a role in the mechanism
underlying response to these drugs.
It has recently been demonstrated that HA is involved
in EMT as defects in HAS2 gene knockout mice failed to
undergo EMT that is required for cardiac tissue develop-
ment [38]. This notion was further supported by HAS2
overexpression study whereby increased in HA production
was suﬃcient to induce EMT and acquisition of trans-
formed properties in normal epithelial cells [39]. In another
study, overexpression of E-cadherin negatively regulated
the interaction of HA with its cell surface receptor, CD44
and inhibits CD44-mediated tumor invasion and branching
morphogenesis [40]. These ﬁnding supports the role of HA
in EMT and in the acquisition of malignant phenotype. In
thispaper,weexaminethenatureofHAinteractionwithnon
small lung cancer cell lines relative to EMT.
2.MaterialsandMethods
2.1. Cell Culture. Lung adenocarcinoma cell lines, A549
and H358 cells were purchased from American Tissue
Type Culture Collection (Manassas, VA) and cultured in
RPMI-1640 media supplemented with 5% FBS (Hyclone,
Logan, UT). HAS3 stable transfectants (HAS3) and vector
transfectants (vector-only control) were cultured in RPMI-
1640 supplemented with 5% FBS and 125μg/mL of Zeocin
(Invitrogen, Carlsbad, CA). Cells were grown at 37
◦Ca n d
5% CO2 in a humidiﬁed incubator.
2.2. Plasmid Construction and Preparation of Stable Trans-
fectant. HAS3 cDNA was ampliﬁed by RT-PCR from H358
mRNAusingoligonucleotidesthatincorporatedHindIIIand
XhoI restriction sites using Platinum Pfx DNA polymerase,
sequence was veriﬁed by DNA sequencing and ligated into
pcDNA3.1 vector. The primer sequences are as follows:
HAS3 (HindIII forward primer) 5 -GCGAAGCTTACC-
ATGCCGGTGCAGCTGACGACAGCC-3  and HAS3 (XhoI
reverse primer) 5 -GCGCTCGAGTCACACCTCAGCAAA-
AGCCAAGCTG-3 .H358cellsweretransfectedwithpcDNA
HAS 3 (HAS3) or pcDNA vector (vector-only control) using
Fugene6(Roche,Indianapolis,IN)followingmanufacturer’s
instruction. Stable clones were obtained by 125μg/mL
Zeocin selection and screened for HA synthesizing capacity
(see HA Assay). Cloning reagents and DNA polymerase were
from Invitrogen (Carlsbad, CA).
2.3. Treatment with Growth Factors and Cytokines. A549
cells (5 × 105/dish) were plated in 35mm dishes overnight
in RPMI-1640 supplemented with 5% FBS. Media was
then replaced with RPMI-1640 supplemented with insulin-
transferrin-selenium (ITS) for 16 hours before treatment
with various growth factors or cytokines (Pepro Tech,
Rocky Hill, NJ) for 24 hours. Media was collected for HA
quantiﬁcation (see HA Assay) while cells were harvested
f o rc e l ll y s a t eu s i n gl y s i sb u ﬀer (100mM Tris-HCl, pH7.5,
150mM NaCl, 1% Triton X-100 and protease inhibitors) for
total protein determination by BCA Protein Assay (Pierce,
Rockford, IL).
2.4. RT-PCR Analysis. Total RNA was extracted, from cells
seeded at 5 × 105 cells/35mm dish, with Trizol and reverse
transcribed with Superscript III RT using oligo dT priming
(Invitrogen, Carlsbad, CA) to generate cDNA templates
according to manufacturer’s instructions. Accumulation of
PCR products was measured in real-time by using SYBR
Green PCR Master Mix with 7300 Real-Time PCR System
(Applied Biosystems, Foster City, CA). The sequences ofJournal of Biomedicine and Biotechnology 3
primers are listed in Table 1. The PCR reactions conditions
consisted of a 10 minutes preincubation at 94
◦C followed
by 40 ampliﬁcation cycles as follows: 94
◦Cf o r1 5s e c -
onds and annealing and extension at 60
◦Cf o r1m i n u t e .
The data was normalized to the expression of the house
keeping gene, glyceraldehydes-3- phosphate dehydrogenase
(GAPDH). Quantiﬁcation was performed using the compar-
ative cycle threshold (Ct) method using the formula 2−ΔΔCt
where ΔΔCt = ΔCtsample − ΔCtreference to calculate relative
expression.
2.5. HA Assay. Cells were grown in RPMI-1640 supple-
mented with ITS to determine the amount of HA released
into the media. Cells were plated at 5×105 cells/dish (35mm
dish). Conditioned media was collected at either 24 hours or
48 hours, clariﬁed by centrifugation and analyzed for total
amount of HA using DuoSet HA kit (R and D Systems,
Minneapolis, MN). Media was diluted between 10- and 100-
foldsothatthesampleswerewithintherangeofthestandard
curve of the DuoSet assay. Plate preparation and assay
procedures were performed according to the manufacturer’s
p r o t o c o l s .T h ev a l u e sa r en o r m a l i z e dt ot o t a lp r o t e i na n d
expressed as nanograms/mL of HA/μg of protein.
2.6. Immunoﬂuorescence Staining. A549 cells were seeded
on 4-well chamber slides (Nunc, Rochester, NY) at cells
seeded at 1 × 105 cells/well and treated with growth factors
and cytokines for 24 hours following overnight incubation
in serum-free media. In the case of HAS3 and vector-
only control transfectants, these cells were plated in 4-well
chamber slides for 48 hours in serum containing media. The
cells were then ﬁxed with 4% formaldehyde in phosphate
buﬀered saline (PBS) for 15 minutes at RT, washed with
PBS, permeabilized with 100% ice-cold methanol at −20
◦C
for 10 minutes, washed with PBS and blocked with PBS
containing 5% of normal goat serum and 0.3% Triton X-
100 for 1 hour. They were then incubated with the primary
antibody to either E-cadherin (#3195) (1 : 100) or vimentin
(#3932) (1 : 50) (Cell Signaling Technology, Danvers, MA)
overnight at 4◦C, washed with PBS and then counterstained
with secondary antibodies conjugated with TRIC (1 : 100,
Pierce, Rockford, IL) for 1.5 hours. After washing, the
coverslips were attached to glass slides with mounting media
containing 4 ,6-diamidino-2-phenylindole (DAPI) (Vector
Laboratories, Burlingame, CA) and edges sealed with nail
polish.Theslideswereexaminedandphotographedusingan
Olympus BX41 microscope (Olympus, Center Valley, PA).
2.7. Particle Exclusion Assay. Pericellular HA matrices were
visualized using a particle exclusion assay as described by
Knudson [41]. Brieﬂy, 1 × 105 cells cells were treated in the
absence or presence of TGF-β1 in combination with IL-
1β (10ng/mL each) for 24 hours followed by treated for 2
hours in the absence or presence of 10units/mL Streptomyces
hyaluronidase (Sigma, St. Louis, MO). In the case of HAS3
and vector-only control transfectants, they were incubated
overnight in serum containing media and then treated with
or without 10units/mL Streptomyces hyaluronidase for 2
hours. The media was aspirated and the cells were washed
and further incubated with 0.75mL of formalin ﬁxed horse
erythrocytes (108 per mL) in PBS containing 0.1% BSA
for 15 minutes. At which time, cells were viewed and
photographed with an inverted phase-contrast microscope
(Nikon, Melville, NY). The HA matrix was evidenced by
halossurroundingthecellsfromwhichtheﬁxederythrocytes
wereexcluded.Cellswerephotographedatamagniﬁcationof
400x.
2.8. Cell Proliferation Assay. Cell proliferation was assessed
using the Cell Titer 96 Aqueous One Solution Cell Pro-
liferation Assay (MTS) (Promega, Madison, WI) according
to manufacturer’s instructions. Cells (A549@ 5000cells/well;
H358@ 10,000cells/well) were plated in 96-well plate in
RPMI-1640 supplemented with 5% FBS and allowed to
attached overnight. Next day, media was replaced with
RPMI-1640 supplemented with ITS for another 24 hours
beforeitwassubjectedtotreatmentwithdiﬀerentconcentra-
tions of EGFR-TKI, Iressa (AstraZeneca, Wilmington, DE)
ranging from 0.5μMt o1 0 μM in the absence or presence
of either 500μg/mL of 132kDa HA (R and D Systems,
Minneapolis, MN) or 500μg/mL HA plus 10units/mL of
Streptomyces hyaluronidase. In the case of H358 HAS3
and vector-only control, cells were cultured in RPMI-1640
supplemented with ITS for 48 hours before treatment with
EGFR-TKI was commenced. Following 72 hours treatment,
MTS reagent was added, incubated for 1 to 2 hours and
absorbance measured at 490nm in a FLUOstar Optima
96-well plate reader (BMG Labtech, Durham, NC). All
experimental data points were set up in six wells. The data
was expressed as percentage growth relative to that of the
untreated control cells.
2.9. Cell Invasion Assay. The ability of cells to migrate
through a Matrigel basement membrane matrix and ﬁlter
was measured in a Matrigel invasion chamber (BD Bio-
sciences, San Jose, CA) with 8μmm e m b r a n ep o r e .A f t e r
rehydration for 2 hours, 1 × 105 cells in RPMI-1640 were
applied to the upper chamber while the lower chamber
contained RPMI-1640 supplemented with 5% FBS that acts
as a chemoattractant. After incubation at 37
◦C for 72 hours,
the upper chamber were removed and placed into a clean
well with RPMI-1640 containing 8μM Calcein AM (Sigma,
St. Louis, MO) for 20 minutes at 37
◦C. At which time,
media was removed from the upper chamber and cells
attached to the lower surface of the ﬁlter were isolated by
placing the insert in trypsin solution without phenol red
for 10 minutes at 37
◦C. Aliquots of the trypsinate were
then assayed at excitation wavelength 480nm and emission
wavelength 520nm in a FLUOstar Optima 96-well plate
reader. To determine the invaded cell number, a ﬂuorescent
cell dose curve was generated by plotting a graph with
the y-axis representing ﬂuorescence units against the x-axis
representing diﬀerent cell numbers.
2.10. MMP2 and MMP9 Zymography. Conditioned media
was obtained from HAS3 and vector-only control cells that4 Journal of Biomedicine and Biotechnology
Table 1: Primer sequences for real-time PCR.
Genes Primer sequences (forward/reverse) Size
bp
Annealing
temperature
◦C
Accession number
HAS1 GCTCAGCATGGGTTATGCTACCGTTGTACAGCC-
ACTCACGGAAG 133 58 NM 001523.1
HAS2 AAGAAAGCTCGCAACACGTAACGCACACCTCCA-
ACCATGGGATCTTCT 220 60 NM 005328.1
HAS3 CTTCTTTGTGTGGCGCAGCCACCTGGATGTAGT-
CCACCGAAT 199 58 NM 005329.1
MMP9 ACCTGAGAACCAATCTCACCGACAGGAAGGTTT-
GGAATCTGCCCAGGTCTGG 229 62 NM 004994.2
MMP2 ACAAATATGAGAGCTGCACCAGCGTTGGTGTAG-
GTGTAAATGGGTGCC 214 59 NM 004530.2
GAPDH GTCAACGGATTTGGTCGTATTGGGTGCCATGGG-
TGGAATCATATTGG 142 58 NM 002046.3
were cultured for 48 hours in RPMI-1640 supplemented
with ITS. The media was concentrated using Microcon
YM-10 spin column (Millipore, Billerica, MA) and protein
concentrationwasdeterminedbyBCA ProteinAssay(Pierce,
Rockford, IL). Equal amount of protein (20μg) was loaded
onto an 8% SDS polyacrylamide gel that contains 0.1%
(w/v) gelatin and was run under nonreducing conditions.
The gel was then incubated in 2.5% Triton X-100 in 50mM
Tris-HCl for 1 hour and subsequently incubated in a buﬀer
containing 150mM NaCl, 10mM CaCl2, 0.02% NaN3,a n d
50mM Tris-HCl, pH 7.5 at 37
◦C for 48–72 hours. The gel
was then stained with 0.25% Coomassie Blue and proteolysis
was detected as a white band against a blue background and
documented using gel imaging system (Alpha Innotech, San
Leandro, CA). The zymogram image was reversed with the
dark bands indicating MMP2 and MMP9 activities.
2.11. Statistical Analysis. The statistical signiﬁcance of the
data was determined with Student’s t-test. Statistical signif-
icance was indicated by P<. 05.
3. Results
3.1. Cytokines and Growth Factor Increases HA Production
in A549 Cells. Present in the extracellular milieu of lung
tumors are various cytokines and growth factors that are
secreted by tumor cells, ﬁbroblasts and immune cells [42,
43]. We tested various cytokines and growth factor for their
ability to enhance HA production in A549 cells, a lung
adenocarcinoma to assess its role in NSCLC as HA has
been implicated to play a role in numerous types of cancer
including breast, prostate, and colon cancers [3].
A549 cells do not expressed HAS1 mRNA but tran-
scripts for HAS2 and HAS3 were detected (Figure 1(a))
in unstimulated cells with HAS3 being the more abundant
transcript that was approximate 2-fold higher as assessed
by quantitative real time RT-PCR (data not shown). Next
the eﬀect of speciﬁc growth factors and cytokines on HA
production was determined. When A549 cells were treated
individually with EGF (50ng/mL) or IL-1β (10ng/mL), an
increased in both mRNA for HAS2 and HAS3 was observed
at24hoursforEGF(2-foldforHAS2,1.4foldforHAS3)and
IL-1β (4.5-fold for HAS2, 2.9-fold for HAS3) (Figure 1(b)).
Treatment with TGF-1β (10ng/mL) resulted in a modest
increase in HAS2 (1.5-fold) with a little or no change
in HAS3 (Figure 1(b)). However, combination treatments
resulted in a substantial increase in both HAS transcripts
for TGF/EGF (10ng/mL and 50ng/mL, resp.), (5-fold for
HAS2, 2 fold for HAS3), and TGF/IL (10ng/mL each) (5.2-
fold for HAS2 and 4.7-fold for HAS3). In each case, these
factors tested had a greater stimulatory eﬀect on HAS2
than HAS3 mRNA while no HAS1 transcript was detected
(data not shown). In addition, induction of HAS transcripts
paralleled with total increased in HA production resulting
from these treatments except for TGF whether no change
was observed (Figure 1(c)). Since TGF/IL resulted in the
highest HA stimulation at 14.09 ± 0.39ng/mL of HA/μg
of protein, this culture was assessed in the assembly of
HA-dependent pericellular matrices as visualized by particle
exclusion assay, a frequently used test for HA coat formation
and HA synthesis [41]. Control A549 cells do not exhibit
these matrices whereby the ﬁxed red blood cells closely
abutted the surface of each cell (Figure 1(d),P a n e lA :
Control). However, when treated with TGF/IL, the cells
appear to be surrounded by a clear halo as the red blood
cells were not able to penetrate the matrices (Figure 1(d),
Panel B: TGF+IL) and the matrices disappears following
treatment with Streptomyces hyaluronidase (Figure 1(d),
PanelC:TGF+IL+SH),anenzymespeciﬁcforHA,indicating
that the assembly of the matrices is HA-dependent.
3.2. Combination of TGF and IL Treatment Induces
Mesenchymal-Like Phenotype in A549 Cells. It was also noted
that combination treatment with TGF/IL resulted in a
change in cell phenotype from epithelial-like that closely
adhered to each other to a more ﬁbroblast-like appearance
(Figure 2, Panel (a) and (d): Phase contrast). This shift
in morphology could represent a transition from epithelial
to mesenchymal phenotype. To determine whether TGF/IL
treatment of A549 cells promotes this transition, we detectJournal of Biomedicine and Biotechnology 5
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Figure 1: Eﬀect of growth factors and cytokines on HA production. (a) Expression of HAS mRNA in A549 cells as visualized by ethidium
bromide staining of agarose gel. A549 cells were treated with or without various growth factors and cytokines for 24 hours in RPMI-
1640 supplemented with ITS following overnight serum starvation and assayed for (b) mRNA expression for HAS2 (open bar) and HAS3
(close bar) by quantitative real time RT-PCR, and (c) total HA production using DuoSet HA kit. (d) HA-dependent pericellular matrix was
visualized by particle exclusion assay following 24 hours incubation with or without combination treatment with 10 ng/mL each of TGF-β1
and IL-1β: Panel (a), Control; Panel (b),T G F + I L ;Panel (c), 2 hours incubation with 10units/mL of Streptomyces hyaluronidase following
treatment with TGF+IL. The experiments were repeated three times and analyzed in triplicate. Representatives are shown for (b) and (c).
(Values are mean ±SD, n = 3, ∗P<. 05).
the presence for E-cadherin as well as vimentin that are
epithelial and mesenchymal markers, respectively in these
cells by immunocytochemistry. Control A549 cells expressed
strong staining for E-cadherin (Figure 2, Panel (b)) with no
evidence of vimentin expression (Figure 2, Panel (c)) while
treatment with TGF/IL cells expressed strong staining for
vimentin (Figure 2, Panel (f)) with reduced staining for E-
cadherin (Figure 2, Panel (e)) indicating that combination
treatment of these cytokines is able to induce EMT-like
transition in A549.
3.3. Overexpression of HA Induces Mesenchymal Character-
istics in H358 Cells. We next asked if an increased in HA
production can induce the transition from an epithelial-like
to mesenchymal-like phenotype in NSCLC. To address this
question, we transfected H358 cells, another lung adenocar-
cinoma cell line that is more epithelial-like in phenotype as
compared to A549 cells [33] with HAS3 gene to generate
a stable cell line that overproduce HA. Overexpression
of HAS3 gene induced over 200-fold increased in HAS3
transcript as compared to vector-only control (Figure 3(a))
resulting in 115 ± 12.33ng/mL of HA/μg of protein while
the vector-only control produced 0.74 ± 0.085ng/mL of
HA/μg of protein (Figure 3(b)). This observed increased in
HA production was also supported by particle cell exclusion
assay whereby HAS3 transfectant assembled a pericellular
coat (Figure 3(c), Panel (b): HAS3) that was HA-dependent
as treatment with Streptomyces hyaluronidase (Figure 3(c),
Panel (c): HAS3+SH) resulted in the loss of the matrix
while the vector-only control showed an absence of a cell
coat (Figure 3(c), Panel (a): Vector-only). We next stained
these cells for E-cadherin and vimentin expression to assess
whether HA overexpression is involved in EMT-like transi-
tion in NSCLC cell line. Vector-only control cells were more
compact and adhered to one another (Figure 3(d),P a n e l
(a)) with a strong staining for E-cadherin (Figure 3(d)c,
Panel (b)) at the cell surfaces and no staining for vimentin
(Figure 3(d), Panel (c)). On the other hand, HAS3 over-
expressing cells tend to spread and are more elongated in
appearance (Figure 3(d), Panel (d)) with weaker staining for
E-cadherin (Figure 3(d), Panel (e)) that is disperse within
the cytoplasm while vimentin is strongly expressed in the
cytoplasmofthesecells(Figure3(d),Panel(f)).Theseresults
support the contribution of HA in inducing morphological
and biochemical changes in cells resulting in a mesenchymal
phenotype in NSCLC cells.6 Journal of Biomedicine and Biotechnology
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Figure 2: Combination treatment with TGF-β1a n dI L - 1 β of A549 cells induces mesenchymal-like phenoptype. A549 cells following
overnight serum starvation were treated with 10ng/mL each of TGF-β1a n dI L - 1 β for 24 hours. Following which time, the cells were ﬁxed,
permeabilized, and stained with antibody against E-cadherin ((b) and (e)) a n dv i m e n t i n( (c) and (f)) and nuclei were counterstained using
4 ,6-diamidino-2-phenylindole. Cells in (a) and (d) were photographed in a phase-contrast microscope. Scale bar: 10μm.
3.4. Increased HA Production Promotes Cell Invasion and
Enhanced MMP2 and MMP9 Activities in H358 Cells.
One of the functional characteristics of mesenchymal-like
cells as a result of the loss of cell-cell adhesion is the
acquisition of invasion ability [27]. To determine whether
HAS3 overexpressing cells that produced increased amount
of HA were more invasive as compared to the vector-
only control, an invasion assay was performed. As shown
in Figure 4(a), HAS3 transfectants had more cells that
transverse through the Matrigel as compared to the vector-
only control, suggesting that overexpression of HA can
promote an increased in invasive ability. As MMP2 and
MMP9areinvolved in invasion [44, 45],we assessedwhether
an increased in HA production is able to induce the
production of these MMPs in NSCLC cell line. Over 7-
fold increased in both MMP9 and MMP2 transcripts were
observed in HAS3 transfectant as compared to the vector-
only control (Figure 4(b)) as determined by quantitative
real time RT-PCR. However, MMP2 transcript was approx-
imately 30-fold less than MMP9 transcript in both vector-
only control and HAS3 transfectants (data not shown). This
result is supported by gelatin zymography that indicated
a strong MMP9 activity at 97kDa with a weaker MMP2
activity at 72kDa (Figure 4(c)) suggesting that HA is
able to induce MMP production to promote cell invasion
in lung adenocarcinoma that have undergone EMT-like
transition.
3.5. Increased HA Production Reduces Sensitivity to EGFR-
TKI in A549 and H358 Cells. EGFR has been shown to
be overexpressed in human cancers including NSCLC and
overexpression has been shown to correlate with poor
survival [32, 46]. Inhibitors of EGFR have been used to
block EGF signaling pathway as a treatment option in
NSCLC [32, 47]. As previous studies have shown that
HA can promote chemoresistance in diﬀerent cancer types
including lung [23]a n dm y e l o m a[ 22] cancers, we wanted
t oe x a m i n ew h e t h e rH Ai sa b l et op r o m o t ec e l ls u r v i v a l
by reducing sensitivity of NSCLC cell lines to EGFR-TKI.
We evaluated a range of concentrations of exogenous HA
(132kDa) in A549 cells. This well diﬀerentiated adenocar-
cinoma has an intermediate sensitivity to EGFR-TKI [33]
showed that increasing concentration of HA reduced the
cells sensitivity to the inhibitor and thereby promoted cell
survival (Figure 5(a)). Furthermore, coincubation of HA
with Streptomyces hyaluronidase resulted in the loss of this
protective eﬀect indicating that HA has a role in promoting
resistance to EGFR-TKI (Figure 5(a)). It has previously
been observed that EMT is a determinant of sensitivity
of NSCLC cell lines to EGFR-TKI [33, 34] and since HA
can promote EMT as presented in the current study, we
assess whether overproduction of HA could play a role in
reduced sensitivity to EGFR-TKI. HAS3 overexpressing cells
showed no cell death at the concentrations of EGFR-TKI
tested while vector-only control exhibited a steady declineJournal of Biomedicine and Biotechnology 7
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Figure 3: Enhanced HA production promotes mesenchymal-like phenotype in H358 cells. H358 cells were stably transfected with either
vector only acting as a control or HAS3 gene. Stable transfectants were assessed for (a) HAS3 mRNA expression by quantitative real time
RT-PCR; (b) total HA production; (c) HA-dependent matrix visualized by particle exclusion assay; (d) expression of E-cadherin ((b) and
(e)) and vimentin ((c) and (f)) by immunocytochemistry using the antibody against E-cadherin and vimentin and counterstained using
4 ,6-diamidino-2-phenylindole. Cells in (a) and (d) were taken using a phase-contrast microscope. Scale bar: 10μm. Three experiments
analyzed in triplicate were carried out for (a) and (b). The data shown is a representative. (Values are mean ±SD, n = 3, ∗P<. 05.)
and at 10μM EGFR-TKI approximately 40% cell death was
observed (Figure 5(b)). These data indicates that HA can
promote cell survival by reducing sensitivity of the cells to
EGFR-TKI. The mechanism by which HA induces resistance
to EGFR-TKI remains to be investigated.
4. Discussion
The close association between high HA level and malignancy
hasbeenreportedinman ydiﬀerenttypesofcancerincluding
breast, ovarian, and bladder cancers [3]. However, there is
only limited information regarding the contribution of HA
in the development of NSCLC. Existing information suggests
thatHAmighthaveacontributingroleinthisprocess[2,23].
The synthesis of HA is a tightly regulated process and is
modulated by cytokines and growth factors in a number of
diﬀerent cancer cells [8–10]. Cytokines and growth factors
are found in the lung tumor microenvironment and are
derivedfromtumorcellsaswellasstromalandinﬂammatory
cells [42]. In this paper, we investigated the eﬀect of EGF, IL-
1β and TGF-β1 in modulating HA synthesis in A549 cells,
a lung adenocarcinoma cell line. These factors were chosen
as they have been reported to play a role in the progression
of lung cancer as elevated expression of EGF, IL-1β,a n d
TGF-β1 have been reported in patients with lung cancer
[48–50]. These factors either separately or in combination
was able to stimulate HAS2 transcript more than HAS3
transcript(Figure1(b))suggestingthatHAS2mRNAismore
responsive to external stimuli which has also been observed
in human mesothelial cells [51]. However, induction of HAS
isoformexpressionsresultedinanincreaseinHAproduction
that mimic the up-regulation of HAS3 isoform, with TGF/IL
combination giving the highest stimulation (Figure 1(c)),
suggesting a dominant role for HAS3 isoform.
I n c r e a s e di nH Ap r o d u c t i o nr e s u l t e di naH A - d e p e n d e n t
pericellular matrix in TGF/IL cultures (Figure 1(d)) that
could participate in biological processes pertaining to
migration and proliferation as these HA-rich matrices have
been reported in migrating and proliferating cells [52]. In
addition, TGF/IL treatment also resulted in morphological
and biological changes whereby there is the combined loss
of staining for epithelial marker, E-cadherin, and a gain in
mesenchymal marker, vimentin (Figure 2) indicating a shift
to a mesenchymal-like phenotype. This ﬁnding suggests that8 Journal of Biomedicine and Biotechnology
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Figure 4: Increased HA production promotes cell invasion and induces enhanced MMP2 and MMP9 activities in H358 cells. (a) Invasive
capacity of HAS3 and vector—only control transfectants were determined using invasion chamber assay (BD Bioscience) as outlined in
Material and Method. (b) mRNA expression for MMP2 and MMP9 were determined by quantitative real time RT-PCR. (c) Following
48 hours incubation in serum-free media, media was collected and gelatinase activities for MMP2 and MMP9 were assayed by gelatin
zymography. The experiments were repeated twice. The data shown for (a) and (b) is a representative. (Values are mean ± SD, n = 3,
∗P<. 05.)
HA synthesis can be modulated by various cytokines and
growth factors in NSCLC. Increase in HA level might play
a role in the EMT-like transition in NSCLC as HA has been
showntobeinvolvedinEMTinnormalcardiacdevelopment
[38].
To deﬁne the role of HA in EMT-like process in
NSCLC, we overexpressed HAS3 gene in H358 cells as these
cells exhibit a more epithelial phenotype as compared to
A549 [33]. Overexpression of HAS3 gene in H358 resulted
in a change is morphology from a more compact and
cobblestone-like appearance to cells that are elongated in
shapewithaconcomitantappearanceofvimentinexpression
and a reduced staining for E-cadherin, indicating a gain in
mesenchymal-like phenotype (Figure 3(c)). Our ﬁnding is
in agreement with a report that showed HA can induced
EMT-like transition and acquisition of transformed char-
acteristics in normal epithelial cells [39]. Moreover, it has
been reported that the HA-CD44 axis plays an important
role in morphogenesis in mammalian organogenesis. In
this context, overexpression of E-cadherin, in cells with
low levels of E-cadherin expression, negatively modulates
HA interaction with its receptor, CD44, that leads to the
inhibition of CD44-mediated cell invasion and branching
morphogenesis [40]. Our study indicates that increase in
HA production can modulate cell surface expression of
E-cadherin and promote a shift to a mesenchymal-like
phenotype in NSCLC. Therefore, this result suggests that
there is a cross-talk between E-cadherin and HA regulation.
Although the mechanism by which HA mediates this eﬀect
in NSCLC remains to be studied it may be possible that
anomalous overexpression of HA destabilizes the balance
in normal epithelial cells with high levels of E-cadherin
expression and induces a shift to an EMT diﬀerentiation
process.
One of the characteristic of cells that have undergone
EMT is the acquisition of an invasive phenotype [27]. We
observed that overexpression of HAS3 gene in H358 resulted
in the cells were more invasive compared to vector-only con-
trol cells (Figure 4(a)). MMP2 and MMP9 have been impli-
cated to play a role in cell invasion and metastasis as they are
involved in the turnover of extracellular matrix components
in the basement membrane [44, 45]. In our system, both
MMP9 and MMP2 transcripts were elevated with the MMP9
mRNA expression being more abundant (Figure 4(b))a n d
this was reﬂected by an increased in their activities as
assessed by the gelatin zymography (Figure 4(c)). Our data
supports that increased HA production is able to stimulate
the production of MMP2 and MMP9 leading to a moreJournal of Biomedicine and Biotechnology 9
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Figure 5: Exogenous HA and overexpression of HAS3 gene reduces sensitivity to EGFR-TKI in A549 and H358 cell lines. (a) A549 cells
were seeded in a 96-well ﬂat bottom plates and treated with either 250μg/mL or 500μg/mL of 132kDa HA in the absence or presence of
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hyaluronidase were coincubated with 500μg/mL HA and treated with varying concentration of EGFR-TKI for 72 hours. The in vitro EGFR-
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were repeated three times. A representative is shown for (a) and (b). (Values are mean ±SD, n = 6, ∗P<. 05.)
invasive phenotype in NSCLC cell line. This is in line with
a recent report that demonstrated that normal epithelial cells
that have undergone EMT following overexpression of HAS2
gene also induced elevated expressions of MMP9 and MMP2
[39]. Further, treatment with exogenous HA was also able to
stimulate MMP2 secretion in small cell lung cancer [25].
EGFR is overexpressed in human cancer including
NSCLC and is correlated with poor prognosis [46]. EGFR-
TKIs have been used in the treatment of NSCLC that
produced a response rate of 9 to 27% [53–55]. To improve
the treatment outcome, extensive investigations have been
carried out to identify the underlining causes for the low
response rate [56, 57]. One such ﬁnding indicated that
EMT is a determinant of sensitivity of NSCLC to EGFR
inhibition whereby tumor cells exhibiting mesenchymal-like
phenotypes were more resistant to EGFR-TKI [33, 34]w h i c h
could be attributed to kinase switching to alternate autocrine
signaling thereby attenuate the dependence of EGFR signal-
ing [58]. Further, a study showed that restoring E-cadherin
expression in EGFR-TKI resistance cells increased sensitivity
to EGFR inhibition [37] that implies EMT has a contributing
role in EGFR-TKI resistance. Additional data to support
this hypothesis was from a study that reported that patients
with epithelial-like NSCLC that showed strong E-cadherin
staining exhibited a signiﬁcant longer time to progression
[34]. Our ﬁnding showed that H358 that have been induced
to undergo EMT-like transition by overexpression of HAS3
were more resistant to EGFR-TKI treatment, as compared
to vector-only control. There was no detectable cell death
at 10μM EGFR-TKI in the HAS3 transfectants while control
cellsgrowthratewasreducedby40%(Figure5(b)).Similarly,
addition of exogenous HA to A549 cells showed more
resistance to EGFR-TKI and this resistance was abolished
with coincubation with Streptomyces hyaluronidase indicat-
ing the role of HA in promoting resistance to EGFR-TKI
(Figure 5(a)). Studies have also documented that interaction
between HA and its receptor, CD44 induces chemoresistance
in NSCLC [23]a sw e l la si nm y e l o m ac e l l s[ 22]a n d
promote survival. Thus, this implies that HA can promote
cell survival by inducing drug resistance to both EGFR-TKI
and chemotherapeutic drugs.
In conclusion, our result suggests that HA is involved
in EMT in NSCLC. Overexpressing HAS3 in H358 cells
results in loss of immunoreactivity for E-cadherin and gain
of vimentin expression. These cells also showed enhanced
MMP2 and MMP9 activities and were more invasive. Finally,
these cells were also more resistance to treatment with
EGFR-TKI. In addition, we also demonstrated that various
cytokines and growth factors can stimulate HA production
in a NSCLC cell line that could be a contributing factor in
the EMT-like transition observed in the cytokines-treated
cultures. Taken together, these results support that HA
can regulate epithelial to mesenchymal-like transition and
therefore contribute to tumorigenesis. Thus, the control
of HA level may be a potential target for therapeutic
intervention for managing this disease.10 Journal of Biomedicine and Biotechnology
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